Results 181 to 190 of about 3,963,204 (295)

Immune checkpoint inhibitors in HIV infection: current evidence on viral reservoir regulation and immune restoration. [PDF]

Front Immunol
Wang Y, Huang X, Zheng L, Luo L, Li T, Cao W.   +5 more
europepmc   +1 more source

Untangling CSR Decoupling: Board Attributes Effects and the Unexplored Moderating Role of Board Gender Diversity

Business Ethics, the Environment &Responsibility, EarlyView.
ABSTRACT This study investigates the phenomenon of corporate social responsibility (CSR) decoupling, wherein firms' CSR disclosures diverge from their actual CSR performance, often resulting in misleading portrayals of environmental and social commitments commonly associated with greenwashing.
María Consuelo Pucheta‐Martínez, Isabel Gallego‐Álvarez, Inmaculada Bel‐Oms   +2 more
wiley   +1 more source

Comparative effectiveness of chimeric antigen receptor (CAR) T‐cell therapy versus historical controls in patients with relapse/refractory aggressive B‐cell lymphoma: An indirect treatment comparison in the real‐world setting

British Journal of Haematology, EarlyView.
Summary Single‐arm studies demonstrate dramatic improvements in survival in patients with relapsed/refractory (R/R) aggressive B‐cell lymphomas but with significant toxicities and at exceptionally high costs. The objective of this study was to evaluate the real‐world health outcomes of aggressive B‐cell lymphoma patients treated with publicly funded ...
Pierre J. A. Villeneuve, Lee Mozessohn, Nibene H. Somé, Rebecca E. Mercer, Lisa Masucci, Tom Kouroukis, Chris Bredeson, Suriya Aktar, Qi Guan, Anca Prica, Christine I. Chen, Danielle Rodin, Matthew Cheung, Munaza Chaudhry, Scott Gavura, Cassandra McKay, William W. L. Wong, Kelvin K. W. Chan   +17 more
wiley   +1 more source

Identification of a Novel Small Molecule Facilitating HIV Elimination by the "Shock-And-Kill" Approach. [PDF]

J Med Virol
Hara Y, Kitamura H, Matsuda K, Fujisaki C, Sukegawa S, Tanimoto K, Maeda K, Takeuchi H.   +7 more
europepmc   +1 more source

SAKK 35/14 randomized trial of rituximab with or without ibrutinib for patients with untreated follicular lymphoma

British Journal of Haematology, EarlyView.
Summary The randomized phase II SAKK 35/14 trial, conducted by the Swiss Group for Clinical Cancer Research (SAKK) and the Nordic Lymphoma Group (NLG), compared efficacy and safety of rituximab (375 mg/m2 intravenously for 4 weeks followed by maintenance every 2 months for 24 months) plus placebo (arm A) versus the same schedule of rituximab plus ...
Maria Cristina Pirosa, Marianne Brodtkorb, Sämi Schär, Björn E. Wahlin, Micaela Hernberg, Michael Pedersen, Anastasios Stathis, Thilo Zander, Urban Novak, Thorsten Zenz, Natalie Fischer, Fatime Krasniqi, Felicitas Hitz, Ann‐Sofie Johansson, David Löfgren, Peter Albert Meyer, Anne Turid Bjørnevik, Giulio Sartori, Stefanie Hayoz, Andrea Fuhrer, Luzia Steiner, Francesco Bertoni, Luca Ceriani, Stefan Dirnhofer, Emanuele Zucca, Bjørn Østenstad   +25 more
wiley   +1 more source

Quantum dot (QD)-based silicon as an efficient catalyst for the one-pot synthesis of polynuclear acridines: molecular docking investigation of putative anti-tubercular and anti-HIV drug candidates. [PDF]

RSC Adv
Tarek M, Said GE, Al-Omar MA, Almehizia AA, Naglah AM, Alshammari A, Ghabbour HA, Khatab TK.   +7 more
europepmc   +1 more source

Cancer pain: current practice and emerging targets

British Journal of Pharmacology, EarlyView.
Cancer pain (CP) arises from a complex interplay between the tumour and its microenvironment. Many patients experience a mixed pain phenotype that encompasses nociceptive, neuropathic and neuroinflammatory mechanisms, and vary across tumour type and disease stage. Despite decades of intensive research, the mainstay of cancer pain treatment is still non‐
Yi Ye, Marcin Chwistek, Zhiting Gong, Vanessa Uzonwanne, Xiaojie Shi, Arpad Szallasi   +5 more
wiley   +1 more source

A case of transient hepatocellular injury in an HIV monoclonal antibody trial. [PDF]

Int J STD AIDS
Harkoo I, Sobia P, Archary D, Garrett N, Mahomed S.   +4 more
europepmc   +1 more source

Peripheral targets for neuropathic pain

British Journal of Pharmacology, EarlyView.
Neuropathic pain represents a significant clinical challenge, with still limited pharmacological approaches to symptomatic relief. This review focuses on molecular targets implicated in neuropathic pain, particularly those involved in peripheral mechanisms. Using the IUPHAR/BPS database of biological targets, their occurrence together with ‘neuropathic
Amirhossein Afsharipour, Cosmin I. Ciotu, Felix J. Resch, Michael J. M. Fischer   +3 more
wiley   +1 more source

Occult hepatitis B and risk of reactivation following switch to non-hepatitis B virus-active antiretroviral therapy in people with HIV. [PDF]

AIDS
Lapadula G, Soria A, Puoti M, Bonfanti P.   +3 more
europepmc   +1 more source